Track Leap Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Leap Therapeutics, Inc. LPTX Open Leap Therapeutics, Inc. in new tab

0.7696 USD
EPS
-1.58
P/B
2.24
ROE
-183.72
Beta
0.09
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 18, 2026
EPS-1.58
Book Value0.91
Price to Book2.24
Debt/Equity0.68
% Insiders11.911%
Estimates
Forward P/E-3.87
Forward EPS-1.25

DCF Valuation

Tweak assumptions to recompute fair value for Leap Therapeutics, Inc. (LPTX)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Leap Therapeutics, Inc. Logo Leap Therapeutics, Inc. Analysis (LPTX)

United States Health Care Official Website Stock

Is Leap Therapeutics, Inc. a good investment? Leap Therapeutics, Inc. (LPTX) is currently trading at 0.7696 USD.

Earnings Schedule: Leap Therapeutics, Inc. is expected to release its next earnings report on May 18, 2026. The market consensus estimate for Forward EPS is -1.25.

Investor FAQ

Does Leap Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Leap Therapeutics, Inc.?

Leap Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 18, 2026. The company currently has a trailing EPS of -1.58.

Company Profile

Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.

Exchange Ticker
NMS (United States) LPTX

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
June 21, 2023 0.100000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion